Comparison of Effectiveness Between Vedolizumab and Ustekinumab in Crohn’s Disease: A Real-World Multicenter Study From Gün-Türk IBD Group, Turkey

Background and Aims: Optimal sequencing of therapy in Crohn’s disease (CD) after anti-tumor necrosis factor (TNF) failure remains uncertain. We compared the real-world effectiveness and safety of vedolizumab (VDZ) and ustekinumab (UST) in this setting. Materials and Methods: This retrospective multicenter cohort included 482 patients with moderate-to-severe CD from 14 tertiary centers in Turkey who received VDZ (n = 247) or UST (n = 235) after ≥1 anti-TNF. Clinical remission (CR; Harvey–Bradshaw Index <5) and steroid-free CR (SFCR) at weeks 14 and 52 were primary outcomes. Long-term response, treatment persistence, and safety were also assessed using inverse probability of treatment weighting. Results: At week 14, UST showed higher CR [adjusted odds ratio (aOR) = 1.49, 95% CI: 1.15-1.94] and SFCR (aOR = 1.42, 95% CI: 1.10-1.83) than VDZ. Superiority persisted in patients with prior biological exposure, though outcomes were similar among those with ≥2 biologics. At weeks 52 and 104, CR and SFCR rates were comparable between groups. Treatment persistence was significantly greater with UST (78.5% vs. 53.1% after inverse probability of treatment weighting; aOR = 3.22, 95% CI: 2.43-4.27), and secondary loss of response was lower (14.5% vs. 38.5%, P < 0.001). Adverse events were infrequent and similar across groups, with few serious events. Conclusions: In anti-TNF–experienced CD, UST provided superior early remission and higher treatment persistence compared with VDZ, while long-term efficacy and safety were similar. UST may be favored where rapid disease control and treatment durability are required, though both agents remain important therapeutic options.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Gastroenterology
Published
2026-11-19
DOI
https://doi.org/10.1097/mcg.0000000000002474
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparison of Effectiveness Between Vedolizumab and Ustekinumab in Crohn’s Disease: A Real-World Multicenter Study From Gün-Türk IBD Group, Turkey

Göksel Bengı, Banu Kara, Emre Odabaş, Ayhan Hilmi Çekın et al.
Journal of Clinical Gastroenterology
Inflammatory Bowel Disease
article

Comparison of Effectiveness Between Vedolizumab and Ustekinumab in Crohn’s Disease: A Real-World Multicenter Study From Gün-Türk IBD Group, Turkey

Göksel Bengı, Banu Kara, Emre Odabaş, Ayhan Hilmi Çekın, Nevin Oruç, Burak Özşeker, Elmas Kasap, Elif Tuğba Tuncel, Fehmi Ateşž, Hale Akpınar, Filiz Araz, Ümit Karaoğullarından, Nalan Gülşen Ünal, Ferda Akbay Harmandar, Süleyman Dolu, Enver Uçbılek, Nimet Yılmaz, Gülşah Şeydaoğlu, Kadri Atay, Sezgin Barutçu, Engin Altıntaşž, Taner Kara, Galip Egemen Atar, Kadir Gişi, Halil Çapar, Zekiye Nur Harput, Birol Özer, B. Tasdogan, Mesut Kuş, B M Aykut, Orhan Sezgin, Mehmet Ali Şahan, Etibar Mamadov, Deha Çetin, Gözde Derviş Hakim, Sevinç Püren Yücel
article en

Abstract

Background and Aims: Optimal sequencing of therapy in Crohn’s disease (CD) after anti-tumor necrosis factor (TNF) failure remains uncertain. We compared the real-world effectiveness and safety of vedolizumab (VDZ) and ustekinumab (UST) in this setting. Materials and Methods: This retrospective multicenter cohort included 482 patients with moderate-to-severe CD from 14 tertiary centers in Turkey who received VDZ (n = 247) or UST (n = 235) after ≥1 anti-TNF. Clinical remission (CR; Harvey–Bradshaw Index <5) and steroid-free CR (SFCR) at weeks 14 and 52 were primary outcomes. Long-term response, treatment persistence, and safety were also assessed using inverse probability of treatment weighting. Results: At week 14, UST showed higher CR [adjusted odds ratio (aOR) = 1.49, 95% CI: 1.15-1.94] and SFCR (aOR = 1.42, 95% CI: 1.10-1.83) than VDZ. Superiority persisted in patients with prior biological exposure, though outcomes were similar among those with ≥2 biologics. At weeks 52 and 104, CR and SFCR rates were comparable between groups. Treatment persistence was significantly greater with UST (78.5% vs. 53.1% after inverse probability of treatment weighting; aOR = 3.22, 95% CI: 2.43-4.27), and secondary loss of response was lower (14.5% vs. 38.5%, P < 0.001). Adverse events were infrequent and similar across groups, with few serious events. Conclusions: In anti-TNF–experienced CD, UST provided superior early remission and higher treatment persistence compared with VDZ, while long-term efficacy and safety were similar. UST may be favored where rapid disease control and treatment durability are required, though both agents remain important therapeutic options.

Journal of Clinical Gastroenterology
Izmir University (TR), Manisa Celal Bayar University (TR), Başkent University (TR), Dokuz Eylül University (TR), Mardin Artuklu University (TR), Ege University (TR), Antalya Eğitim ve Araştırma Hastanesi (TR), Başkent University Hospital (TR), Sağlık Bilimleri Üniversitesi (TR), Sanko University (TR), Mersin Üniversitesi (TR), Cukurova University (TR), Gaziantep University (TR), Muğla University (TR)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon